1. This article refers to the treatment of the disease or situation caused by the impact of the expression or activity of acrylonitrile / nine (PCSK9) convertase methylene / kexina (PCSK9) through the use of specific PCSK9 antibody or its antigen binding fragment, preferably through the management of this method.Additional value of 3-hydroxi-3-meth-glutaril-coa reductase (HMG-CoA reductase) inhibitor. This document also deals with specific polychlorinated biphenyl9 antibodies or their antigen binding fragments for the treatment of diseases or diseases that are impacted by the performance or activity of polychlorinated biphenyl9.For example, people with dyslipidemia The contract also covers manufactured products, including packaging materials, specific polychlorinated biphenyl antibodies or adhesive fragments of their antigens, and labels or instructions indicating groups of patients who can be treated with these antibodies or fragments, Which group of patients should not be treated with this antibody or fragmentWhat dose should be used. In addition, this document also deals with the method of antibody validity test for specific polychlorinated biphenyl9 antibody or fragment combined with polychlorinated biphenyls antigen, so as to treat certain diseases or diseases and specific patient groups.La presente se refiere a métodos para tratar enfermedades o afecciones en las que la expresión o actividad de la proproteína convertasa subtilisina/kexina tipo 9 (PCSK9) ocasiona un impacto mediante la administración de anticuerpos específicos para PCSK9 o fragmentos de unión al antígeno de los mismos y preferiblemente mediante la administración adicional de un inhibidor de 3-hidroxi-3-metil-glutaril-CoA reductasa (HMG-CoA reductasa). La presente se refiere adicionalmente a anticuerpos específicos para PCSK9 o fragmentos de unión al antígeno de los mismos para su uso en el tratamiento de enfermedades o afecciones en las que la expresión o actividad de PCSK9 ocasionan un impacto
